cor2ed
engage checkpoint medical linkedin twitter
bg

Experts Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice

Experts Knowledge Share: Incorporating PARP inhibitors into prostate cancer clinical practice

On-demand e-learning, video replay and slide set now available

On-demand e-learning, video replay and slide set now available

Prof. Fred Saad, Assoc. Prof. Tanya Dorff, Prof. Gerhardt Attard, Prof. Neeraj Agarwal

In our recent Experts Knowledge Share, world-renowned experts discussed case studies, reviewed the latest data and shared their views. 

Guest expert Prof. Fred Saad joined GU CONNECT members Assoc. Prof Tanya Dorff, Prof. Gerhardt Attard, and Prof. Neeraj Agarwal, along with participants from around the world, to discuss incorporating PARP inhibitors into prostate cancer clinical practice

GU CONNECT invites you to watch the video replay, download the accompanying slides, and take the e-learning using the blue button below the video to claim your CME credit.

 

Image of Prof. Fred Saad
Prof. Fred Saad

Professor and Chairman of Urology, Director of GU Oncology Raymond Garneau Chair in Prostate Cancer

University of Montreal Hospital Center, Canada

Canada

Portrait of Tanya Dorff
Assoc. Prof. Tanya Dorff

Medical Oncologist

City of Hope Comprehensive Cancer Center

United States (US)

Portrait of Gerhardt Attard
Prof. Gerhardt Attard

Medical Oncologist

University College London Cancer Institute

United Kingdom (UK)

Image of Neeraj Agarwal
Prof. Neeraj Agarwal

Medical Oncologist

University of Utah Huntsman Cancer Institute

United States (US)

preview next

Incorporating PARP inhibitors into prostate cancer clinical practice

time | open 78 min |accreditation: EACCME | Dec 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Incorporating PARP inhibitors into prostate cancer clinical practice.

Video Chapters

Chapter 1  00:00     Scene-setting - Prof. Fred Saad

Chapter 2  05:23     Use of PARP inhibitors beyond the first-line setting in mCRPC - Prof. Fred Saad and Prof. Gerhardt Attard

Chapter 3  39:24     Use of PARP inhibitors in the first-line setting in mCRPC - Assoc. Prof. Tanya Dorff and Prof. Neeraj Agarwal

Chapter 4  1:09:50  Questions and panel discussion

Chapter 5  1:14:06   Future perspectives and summary - Prof. Fred Saad

 

Clinical Takeaways

 

  • PARP inhibitors are an important part of the treatment strategy for mCRPC patients

  • mCRPC patients who harbour HRR mutations benefit from PARPi monotherapy following progression on prior novel hormonal agents

  • Treatment with PARP inhibitors plus novel hormonal agents can provide combination benefits in mCRPC patients with or without HRR mutations

  • The future treatment landscape for prostate cancer patients will likely include the earlier introduction of PARPi's and treatment beyond patients with HRR/DRR mutations

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

This educational programme is supported by an Independent Medical Education Grant from AstraZeneca

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

Other programmes developed by Assoc. Prof. Tanya Dorff

Portrait of Tanya Dorff
Assoc. Prof. Tanya Dorff

Medical Oncologist

City of Hope Comprehensive Cancer Center

United States (US)

Other programmes developed by Prof. Gerhardt Attard

Other programmes developed by Prof. Neeraj Agarwal